BDBM185591 US12139488, Example Belvarafenib::US9156852, 116::USRE47451, Example 116

SMILES Cc1ccc2c(c1NC(=O)c3csc4c3ncnc4N)ccnc2Nc5cccc(c5F)Cl

InChI Key InChIKey=KVCQTKNUUQOELD-UHFFFAOYSA-N

Data  13 IC50

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 185591   

TargetSerine/threonine-protein kinase B-raf(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 56nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 7nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetMacrophage colony-stimulating factor 1 receptor(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 10nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetEpithelial discoidin domain-containing receptor 1(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 23nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetDiscoidin domain-containing receptor 2(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 44nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2016
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase B-raf [409-765](Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 56nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetSerine/threonine-protein kinase B-raf [V600E](Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 7nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetMacrophage colony-stimulating factor 1 receptor(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 10nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetEpithelial discoidin domain-containing receptor 1(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 23nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetDiscoidin domain-containing receptor 2(Human)
Hanmi Pharm.

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 44nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase A-Raf(Human)
Université

US Patent
LigandPNGBDBM185591(US9156852, 116 | USRE47451, Example 116 | US121394...)
Affinity DataIC50: 10nMAssay Description:In vitro enzymatic reactions were used for evaluating compounds intrinsic activity against BRAF, CRAF and ARAF. For BRAF and CRAF, 0.375 nM of purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/18/2025
Entry Details
Go to US Patent